EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)

Kyoo Hyun Kim, Minkyu Jung, Hyo Jin Lee, Su Jin Lee, Miso Kim, Mi Sun Ahn, Moon Young Choi, Na-Ri Lee, Sang Joon Shin, Korean Cancer Study Group (KCSG)

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.113312 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Kyoo Hyun Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Antineoplastic Agents, Melanoma, Phenylurea Compounds, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMelanomaPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyridinesSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDisease ProgressionMutationProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

C-KIT mutationCirculating tumour DNAMalignant melanomaRegorafenib

Substanzen

Antineoplastic AgentsKIT protein, humanPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyridinesregorafenib

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine and Cancer Research Institute, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Divison of Hematology-Oncology, Department of Internal Medicine, Ewh…
  • Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, Republic of Korea.
  • Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
  • Department of Internal Medicine, Hemato-Oncology, Inje University Busan Paik Hospital, Busan, Republic of Korea.

Zitieren

APA

Kim, K. H., Jung, M., Lee, H. J., Lee, S. J., Kim, M., Ahn, M. S., Choi, M. Y., Lee, N. R., Shin, S. J., & Korean Cancer Study Group (KCSG) (2023). A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113312

Vancouver

Kim KH, Jung M, Lee HJ, Lee SJ, Kim M, Ahn MS, et al. A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13). European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.113312

BibTeX
@article{Kim2023,
  author = {Kim, Kyoo Hyun and Jung, Minkyu and Lee, Hyo Jin and Lee, Su Jin and Kim, Miso and Ahn, Mi Sun and Choi, Moon Young and Lee, Na-Ri and Shin, Sang Joon and Korean Cancer Study Group (KCSG), Korean Cancer Study Group (KCSG)},
  title = {A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.113312}
}
Kostenlos starten →